What diseases does Aflibercept treat?

Introduction to Aflibercept

Aflibercept is a recombinant fusion protein, designed as a soluble decoy receptor that binds and neutralizes multiple members of the vascular endothelial growth factor (VEGF) family, including VEGF-A, VEGF-B, and placental growth factor (PlGF). Its structure comprises extracellular binding domains from VEGF receptors 1 and 2 fused to the Fc portion of human immunoglobulin G1, which provides it with high affinity for its ligands. By sequestering these pro-angiogenic factors, aflibercept prevents them from binding to and activating their native receptors on the surface of endothelial cells, thereby inhibiting the formation of abnormal new blood vessels (angiogenesis) and reducing vascular permeability. This intriguing mechanism underlies its use in a range of diseases where aberrant angiogenesis plays a critical role.

Overview of Aflibercept in Medicine 
Aflibercept has become a cornerstone in modern medicine, particularly within ophthalmology and oncology. Initially developed for eye conditions that involve abnormal blood vessel growth and leakage, its unique mechanism has allowed it to demonstrate significant clinical benefits over older modalities. Its indications have expanded further as clinical trials and real‐world evidence have supported its utility in treating complex vascular-related disorders beyond ocular diseases. As a result, aflibercept plays an essential role both as a direct therapeutic agent and as part of combination regimens, particularly in anti-angiogenic oncology protocols.

Diseases Treated by Aflibercept

Eye Diseases 
Aflibercept has been a game‐changer in the management of several ocular disorders primarily characterized by pathological angiogenesis and vascular leakage. The key eye diseases treated by aflibercept include:

• Neovascular (Wet) Age-Related Macular Degeneration (nAMD): 
In nAMD, the abnormal growth of blood vessels under the macula leads to fluid leakage, hemorrhage, and ultimately loss of central vision. Aflibercept, through its dual inhibition of VEGF-A and PlGF, has been shown to prevent further neovascularization and reduce the accumulation of subretinal fluid. Clinical studies, including the pivotal VIEW 1 and VIEW 2 trials, demonstrated that aflibercept administered intravitreally results in visual acuity gains comparable to other anti-VEGF agents such as ranibizumab, albeit with a reduced injection burden. Moreover, real-world evidence suggests that, when delivered using treat-and-extend protocols, aflibercept can maintain vision while potentially extending dosing intervals.

• Diabetic Macular Edema (DME) and Diabetic Retinopathy: 
In patients with diabetes, chronic hyperglycemia leads to microvascular damage, resulting in retinal leakage and macular edema. The pathological elevation in VEGF levels not only contributes to vascular leakage but also perpetuates inflammation. Aflibercept’s high binding affinity for VEGF-A, along with its ability to neutralize PlGF, provides superior anatomical outcomes measured by reductions in central macular thickness (CMT) and functional improvements in best-corrected visual acuity (BCVA). Several studies, including large-scale randomized controlled trials, have demonstrated that aflibercept outperforms or is at least noninferior to alternative therapies such as laser photocoagulation, bevacizumab, and ranibizumab in patients with moderate to severe vision loss due to DME.

• Retinal Vein Occlusion (RVO) – Both Central (CRVO) and Branch (BRVO): 
Retinal vein occlusion leads to increased venous pressure and capillary leakage, resulting in macular edema. Intravitreal aflibercept injections have been studied in CRVO, where trials such as COPERNICUS and GALILEO reported significant improvements in BCVA with aflibercept compared to control groups. The consistent reduction in macular edema and the high rates of fluid resolution reported in these trials underscore aflibercept’s efficacy as a treatment option for RVO-associated edema.

• Additional Ocular Conditions: 
Beyond nAMD, DME, and RVO, aflibercept has been investigated in a range of other retinochoroidal disorders where pathological angiogenesis is implicated. These include conditions such as myopic choroidal neovascularization, polypoidal choroidal vasculopathy, and even more rare entities like Coats’ disease. In each of these conditions, the suppression of VEGF and PlGF signaling plays a central role in preventing further damage and preserving vision. 
Furthermore, innovative studies have explored the utility of aflibercept in conditions with inflammatory and angiogenic components, which may include secondary off-label use in diseases like retinoblastoma where angiogenesis supports tumor growth, albeit these uses remain under investigation and are not currently approved indications.

Oncology Applications 
While aflibercept is most prominently used in ophthalmology, it has also garnered approval in specific oncology settings. Its anti-angiogenic effects extend beyond the eye, making it a valuable component in cancer therapy.

• Metastatic Colorectal Cancer (mCRC): 
Aflibercept has been approved for use in combination with FOLFIRI (a chemotherapy regimen including 5-fluorouracil, leucovorin, and irinotecan) in patients with metastatic colorectal cancer (mCRC) who have progressed on an oxaliplatin-containing regimen. The drug works by preventing angiogenesis within the tumor microenvironment, thereby helping to starve tumors of necessary blood supply. The VELOUR trial, a multicenter phase III study, demonstrated that adding aflibercept to FOLFIRI produced statistically significant improvements in overall survival (OS) and progression-free survival (PFS) compared to FOLFIRI alone. Although the survival benefit in terms of median OS was modest, the trial indicated that inhibiting VEGF-mediated angiogenesis could delay disease progression and potentially enhance the efficacy of cytotoxic agents.

• Other Malignancies: 
Preclinical and early-phase clinical studies have evaluated aflibercept in various solid tumors beyond colorectal cancer. Although its robust activity in mCRC has been the most successful, investigations have been conducted in other malignancies such as ovarian cancer, non–small cell lung cancer (NSCLC), and even in combination with other anti-cancer agents for potential synergistic effects. The anti-angiogenic properties of aflibercept theoretically make it applicable to any solid tumor in which neovascularization plays a role. However, its use in these contexts remains investigational and subject to further clinical trial validation.

Efficacy and Safety

Clinical Trials and Studies 
A robust body of evidence supports the efficacy of aflibercept in both ocular and oncologic applications. In ophthalmology, numerous randomized controlled trials and real-world observational studies have validated its clinical benefits. For instance, in nAMD, studies such as the VIEW trials not only demonstrated that aflibercept effectively maintains visual acuity and reduces central macular thickness with a lower injection frequency compared to monthly dosing regimen alternatives but also highlighted its durability when administered in treat-and-extend protocols. In DME, multiple studies have shown significant functional and anatomical improvements, with aflibercept outperforming laser therapy and providing comparable results to other anti-VEGF agents in patients with more severe baseline vision loss. Moreover, clinical trials in CRVO have documented that a high percentage of patients achieve at least a 15-letter gain in BCVA, accompanied by marked reductions in retinal edema.

In oncology, the VELOUR trial stands as a landmark study demonstrating that the combination of aflibercept with FOLFIRI significantly improves survival endpoints in mCRC patients compared to chemotherapy alone. Despite the modest increase in median overall survival of approximately 1.4 months, the trial’s results reveal that aflibercept can alter tumor angiogenesis in a clinically meaningful way.

Side Effects and Safety Profile 
Safety is a critical aspect of aflibercept’s clinical use. In the ocular setting, aflibercept has an established safety profile, with common side effects including transient intraocular pressure increases, mild ocular inflammation, and procedure-related complications typical of intravitreal injections such as floaters or mild discomfort. Serious ocular adverse events, such as endophthalmitis or retinal detachment, remain rare, and the frequency of these complications is comparable to those observed with other intravitreal anti-VEGF therapies.

In oncology, the safety profile of aflibercept is shaped by its systemic administration and anti-angiogenic mechanism. As reported in the VELOUR study, patients in the aflibercept-FOLFIRI arm experienced higher incidences of hypertension, dysphonia, epistaxis, and stomatitis compared to controls. Grade 3 or 4 adverse events occurred more frequently in the aflibercept group, but the adverse events were generally manageable with standard supportive care and dose adjustments. The meta-analysis evaluating hemorrhagic events in cancer patients treated with aflibercept reported an overall incidence of about 22.1% for all-grade hemorrhagic events and 4.2% for high-grade events, indicating a risk that should be weighed when administering aflibercept in the oncology setting.

Comparison with Other Treatments

Alternatives and Comparisons 
Aflibercept is one of several anti-VEGF agents available for the treatment of retinal diseases, with others including ranibizumab and bevacizumab. Comparative studies have focused on varying aspects such as efficacy, durability, dosing frequency, and safety profiles. In head-to-head comparisons, aflibercept has demonstrated noninferiority and, in some cases, superiority in visual acuity outcomes and anatomical improvements, particularly in patients with severe baseline vision loss due to DME. The higher binding affinity of aflibercept for VEGF-A and its ability to neutralize PlGF allow it to potentially offer longer duration of intraocular VEGF suppression compared to ranibizumab and bevacizumab, which may translate into extended dosing intervals and reduced treatment burden.

In oncology, bevacizumab also targets VEGF and is widely used in metastatic colorectal cancer. However, aflibercept’s unique molecular design, capturing a broader spectrum of VEGF ligands (including VEGF-B and PlGF), may offer additional anti-angiogenic benefits that could translate into improved outcomes in combination with chemotherapy. Nevertheless, certain studies have noted that while aflibercept can offer statistically significant improvements in survival endpoints, the clinical significance in terms of overall survival benefit remains modest when compared to its alternatives.

Advantages and Disadvantages 
The principal advantages of aflibercept include its high binding affinity, dual inhibition of VEGF-A and PlGF, and the potential for longer dosing intervals, which can improve patient compliance and reduce clinical workload in retina practices. Its robust efficacy in reducing macular edema and preserving visual acuity has been clearly demonstrated across a spectrum of retinal diseases. In the realm of oncology, its addition to combination therapy regimens for mCRC provides a proof-of-concept for targeting tumor angiogenesis, even though the survival benefits observed are modest.

On the downside, aflibercept is not without limitations. In ophthalmology, the requirement for intravitreal injections can be uncomfortable and carries risks such as intraocular pressure spikes, although these risks are similar to those of other anti-VEGF drugs. In oncology, the increased incidence of adverse events such as hypertension, proteinuria, and hemorrhagic episodes compared to control regimens necessitates close monitoring. Additionally, the cost associated with aflibercept therapy, both in ophthalmology and oncology, can be considerable, adding financial considerations to its clinical use.

Future Directions

Ongoing Research 
Current research efforts continue to refine the use of aflibercept, both by optimizing dosing protocols and by exploring its use in new indications. In ophthalmology, ongoing clinical trials such as those investigating the extended dosing regimen for aflibercept 8 mg are designed to evaluate whether a longer duration of action can be achieved while maintaining efficacy and safety. These trials aim to determine whether the prolonged suppression of VEGF can further reduce the treatment burden on patients while delivering sustained improvements in visual acuity and anatomical parameters.

In oncology, while aflibercept’s use in mCRC is well established, further studies are ongoing to better define its role in complex combination regimens and to explore its potential in other cancer types. Early-phase trials and preclinical studies are investigating its application in ovarian cancer, non–small cell lung cancer, and other solid tumors where angiogenesis is a critical factor. The gradual integration of aflibercept into multi-agent regimens may offer opportunities to enhance its therapeutic index by synergizing with other cytotoxic or targeted therapies. Moreover, translational research is focused on identifying biomarkers that can predict which patients are more likely to benefit from aflibercept, potentially allowing for a more personalized approach to therapy.

Potential New Applications 
Beyond its current approved indications, there are several emerging areas where aflibercept may find new therapeutic roles. One promising area is the use of aflibercept in retinal diseases other than the conventional indications. For example, studies investigating its role in myopic choroidal neovascularization, polypoidal choroidal vasculopathy, and even in chronic degenerative conditions of the retina provide encouraging preliminary data that could broaden its impact in ophthalmology.

In the field of oncology, the intrinsic anti-angiogenic activity of aflibercept makes it an attractive candidate for treating other tumors that rely heavily on neovascularization. Although its current approved use is limited to mCRC, the mechanism of action suggests potential utility in tumors such as advanced ovarian cancer, NSCLC, and other vascularized solid neoplasms. Additionally, innovative preclinical models have begun to explore aflibercept’s effects on rarer conditions such as retinoblastoma, wherein the inhibition of tumor-associated angiogenesis might help control tumor progression and invasion. Future studies are likely to further define these roles and may lead to new combination strategies that harness aflibercept’s unique pharmacologic properties.

Another exciting research direction is in drug delivery and formulation improvements. For example, strategies to convert aflibercept into sustained-release depot formulations or to employ novel delivery systems such as suprachoroidal injections are under active investigation. These advances could potentially reduce the frequency of invasive procedures, enhance patient adherence, and ultimately improve long-term outcomes for chronic diseases requiring continual therapy.

Conclusion 
Aflibercept stands out as a multifunctional therapeutic agent principally used to treat diseases driven by pathological angiogenesis. In the realm of ophthalmology, its primary indications include neovascular (wet) age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. Each of these conditions benefits from aflibercept’s ability to reduce abnormal vascular permeability and neovascularization, thereby preserving central vision and improving anatomical outcomes. Clinical studies and real-world evidence consistently demonstrate that aflibercept can maintain or improve visual acuity and reduce macular thickness, often with the advantage of extended dosing intervals that mitigate the treatment burden on patients.

In oncology, aflibercept has been approved for metastatic colorectal cancer in combination with chemotherapy (FOLFIRI), where its mechanism of action helps inhibit tumor angiogenesis and slightly extend patient survival. Although the survival benefits in oncology have been modest compared to those seen in ocular diseases, these outcomes validate the therapeutic principle of targeting angiogenesis in cancer. Comparative studies have highlighted aflibercept’s advantages over other anti-VEGF agents due to its broader ligand inhibition profile, yet they also underscore the need for cautious management of its systemic side effects.

Looking ahead, ongoing research is paving the way for potential new applications of aflibercept. In ocular care, trials are refining extended dosing regimens and exploring its utility in less common retinal disorders. In oncology, further clinical trials and biomarker-driven studies may expand its indications beyond metastatic colorectal cancer, ultimately leading to more personalized and effective treatment paradigms. Additionally, improvements in drug delivery methods could enhance patient compliance, safety, and overall efficacy.

In summary, aflibercept treats a spectrum of diseases ranging from vision-threatening conditions such as wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion to certain oncologic indications, particularly metastatic colorectal cancer. Its efficacy is supported by a robust body of clinical and real-world evidence, and its unique dual inhibition of VEGF-A and PlGF sets it apart from other anti-VEGF therapies. While it is not without limitations, the evolving landscape of clinical research and development continues to highlight aflibercept’s central role in managing both ocular and systemic diseases, with promising potential for new applications in the future.

Discover Eureka LS: AI Agents Built for Biopharma Efficiency

Stop wasting time on biopharma busywork. Meet Eureka LS - your AI agent squad for drug discovery.

▶ See how 50+ research teams saved 300+ hours/month

From reducing screening time to simplifying Markush drafting, our AI Agents are ready to deliver immediate value. Explore Eureka LS today and unlock powerful capabilities that help you innovate with confidence.